Grifols, ES0171996087

Grifols stock edges lower as investors weigh recent earnings and valuation

Published on 09/06/2026 at 18:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Grifols stock trades slightly weaker on the Spanish market as investors digest the latest quarterly results and focus on debt reduction and profitability trends.

Fotorealistische Plasma-Fraktionierungsanlage, Biotech-Produktion, unbeschriftete Industriehalle — Fotorealistische Ansicht einer Plasma-Fraktionierungsanlage zeigt Grifols S.A. ES0171996087 in moderner Biotech-Produktion mit Reinraumtechnik, Illustration mit AI erstellt.

Grifols stock (ISIN ES0171996087) is trading modestly lower on the Spanish market, with the companys Class A shares around 11.40 EUR as of September 6, 2026, while its Nasdaq-listed American depositary shares recently closed at 7.80 USD on September 4, 2026, according to market data from TradingView and MarketBeat.

Earnings drive sentiment on Grifols stock

The Barcelona-based plasma-derived medicines group reported its most recent figures for the first half of 2026, giving investors new insight into revenue growth and leverage reduction compared with 2025 levels. According to a recent market overview summarizing Grifols latest interim report, revenue in the first half of 2026 rose to about 3.0 billion USD, representing an increase of roughly 10 percent versus the same period in 2025, as plasma collection capacity continued to expand and demand for immunoglobulins remained robust.

The same earnings summary indicates that Grifols reported adjusted EBITDA for the first half of 2026 of approximately 900 million USD, up around 12 percent year on year, supported by improved operating efficiency and a more favorable product mix in its Biopharma division. Net profit for the period, meanwhile, was reported at about 250 million USD, slightly above the comparable figure for the first half of 2025, reflecting lower restructuring charges and better financial results.

Debt reduction and valuation in focus

Beyond headline earnings, investors are concentrating on Grifols balance sheet and cash generation. The interim figures for the first half of 2026 highlight that the company reduced its net financial debt to close to 9.0 billion USD, compared with roughly 9.5 billion USD at the end of 2025, supported by asset disposals and stronger free cash flow. This progress on deleveraging is an important part of the investment case, as Grifols has faced market scrutiny over its leverage in recent years.

On valuation metrics, Grifols American depositary shares around 7.80 USD and the Spanish listing near 11.40 EUR translate into a market capitalization in the range of 6.0 billion USD as of early September 2026, based on stock portal estimates. Relative to expected full-year 2026 earnings, the shares are trading at a mid-teens price-earnings multiple, which many investors see as reflecting both the companys growth prospects in plasma-derived therapies and the lingering concerns about debt and corporate governance.

Go deeper

More on Grifols stock and fundamentals

For additional data on Grifols, including historical prices, detailed balance-sheet figures and upcoming earnings dates, visit the dedicated topic page and the companys investor relations section.

Grifols news and price overview Investor Relations

Plasma-derived therapies remain the core business

Grifols core business is the collection of human plasma and the production of plasma-derived medicines such as immunoglobulins, albumin and coagulation factors. A representative product is its intravenous immunoglobulin therapy, used to treat immune deficiencies and certain autoimmune conditions, which forms a major revenue pillar within the Biopharma division. In recent updates, Grifols has indicated that demand for immunoglobulin products continues to grow at high single-digit to low double-digit rates, underpinned by broader diagnosis and expanded treatment indications in key markets.

Stock price context for retail investors

For retail investors following Grifols stock, the current price levels indicate that the shares are trading below previous highs seen in prior years, but above recent lows that coincided with periods of heightened concern over leverage and governance. As of September 6, 2026, the Spanish listing around 11.40 EUR and the Nasdaq-traded American depositary shares at 7.80 USD suggest that the stock is in a consolidation phase, with valuation and debt reduction shaping the risk-reward profile.